Zenodo (CERN)
open access
Regulatory Strategy, Project Management, and IND Readiness in the Early Development of Dual BAFF and APRIL Neutralization for IgA Nephropathy: A Case Analysis for Pre-IND Meetings and the IND Application for FDA
This article examines early drug development through the lens of regulatory affairs and project management, with emphasis on readiness for Pre-IND meetings and the IND application for FDA. IgA nephropathy (IgAN) is a kidney disease of B-cell origin in which galactose-deficient I
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Mediators of Loin Pain in IgA Nephropathy#852002
- Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy#1058773
- Kidney Precision Medicine Project#905549
- Rituximab in Recurrent IgA Nephropathy#1363700
- Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study#802070
Record · ID 1291702
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive